A Comprehensive Guide to Toxicology in Nonclinical Drug Development (eBook, ePUB)

Redaktion: Faqi, Ali S.

• Format: ePub

Produktbeschreibung

A Comprehensive Guide to Toxicology in Nonclinical Drug Development, Third Edition is a valuable reference providing a complete understanding of all aspects of nonclinical toxicology in pharmaceutical research. This updated edition has been expanded and re-developed covering a wide-range of toxicological issues in small molecules and biologics. Topics include ADME in drug discovery, pharmacokinetics, toxicokinetics, formulations, and genetic toxicology testing. The book has been thoroughly updated throughout to reflect the latest scientific advances and includes new information on antiviral drugs, anti-diabetic drugs, immunotherapy, and a discussion on post-pandemic drug development challenges and opportunities. This is an essential and practical resource for all toxicologists involved in nonclinical testing in industry, academic, and regulatory settings.

• Provides updated, unique content not covered in one comprehensive resource, including chapters on stem cells, antiviral drugs, anti-diabetic drugs, and immunotherapy
• Includes the latest international guidelines for nonclinical toxicology in both small and large molecules
• Incorporates practical examples in order to illustrate day-to-day activities and expectations associated with working in nonclinical toxicology

---

Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.

Produktdetails

• Verlag: Elsevier Science & Techn.
• Seitenzahl: 1020
• Erscheinungstermin: 11. Februar 2024
• Englisch
• ISBN-13: 9780323984621
• Artikelnr.: 69961084

Inhaltsangabe

1. Introduction
Section I. Drug Discovery, Metabolism, and Pharmacokinetics
2. Critical Aspects of Integrated Nonclinical Drug Development: Concepts,
Strategies, and Potential Pitfalls
3. ADME in Drug Discovery
4. Pharmacokinetics and Toxicokinetics
5. Secondary Pharmacology Screening in Drug Discovery
Section II. Toxicological Studies and Ind Application, and First In-Human
Clinical Trial
6. Acute, Subacute, Subchronic, and Chronic General Toxicity Testing for
Preclinical Drug Development
7. Genetic Toxicology Testing
8. Contemporary Practices in Core Safety Pharmacology Assessments
9. Preparation of a Preclinical Dossier to Support an Investigational New
Drug (IND) Application and First-In-Human Clinical Trial
10. Developmental and Reproductive Toxicology
11. Juvenile Testing to Support Clinical Trials in Pediatric Population
12. Preclinical Evaluation of Carcinogenicity Using Standard-Bred and
Genetically Engineered Rodent Models
13. Current Strategies for Abuse Liability Assessment of New Chemical
Entities
Section III. Clinical Pathology, Histopathology, and Biomarkers
14. Clinical Pathology
15. Best Practice in Toxicological Pathology
16. Molecular Pathology: Applications in Nonclinical Drug Development
17. Biomarkers in Nonclinical Drug Development
IV. Biostatistics, Regulatory Toxicology, and Role of Study Directors
18. Biostatistics for Toxicologists
19. Regulatory Toxicology
20. Role of Study Director and Study Monitor in Drug Development Safety
Studies
Section V. Specialty Route of Administration
21. Infusion Toxicology and Techniques
22. Photosafety Assessment
Section VI. Nonclinical Development of Monoclonal Antibodies, Stem Cells,
Oncogenic and Non-Oncogenic Drugs, Oligonucleotides, and Vaccines
23. Preclinical Development of Monoclonal Antibodies
24. Nonclinical Safety Assessment of Cell-Based Therapies
25. Nonclinical Development of Antiviral Drugs
26. Nonclinical Assessment of Anti-diabetic drugs
27. Safety Assessments of Cancer Immunotherapy Drugs
28. Application of Micro-physiological systems to enhance drug safety
assessment
29. Use of Humanized mice in Safety Assessment
30. Safety Assessment of Cell and Gene Therapy
31. Preclinical Development of Oncology Drugs
32. Preclinical Toxicology of Vaccines
33. Overview of the Nonclinical Development Strategies and Class-Effects of
Oligonucleotide-Based Therapeutics
Section VII. Safety Evaluation of Ocular Drugs, Botanical Products, and
Medicinal Devices
34. Safety Evaluation of Ocular Drugs
35. Safety Assessment of Targeted Protein Degraders (TBD)
36. Biocompatibility Evaluation of Medical Devices
Section VIII. Predictive Toxicology, Toxicometabolomics, Toxicogenomics,
and Imaging
37. Application of Evolving Computational and Biological Platforms for
Chemical Safety Assessment
38. Use of Imaging for Preclinical Evaluation
39. Drug Development Challenges and Opportunities Post-Pandemic